IBD meds could treat COVID-19

Reuters Health - 02/10/2020 - Immune-response signatures shared by patients with COVID-19 and patients with inflammatory bowel disease (IBD) suggest a possible role for IBD medications in the treatment of COVID-19, researchers report. "A number of overlapping inflammatory pathways between COVID-19 and IBD imply that some of the pre-existing IBD medications, like IL-12/23 inhibitors or TNF inhibitors, could be repurposed for use in COVID-19 patients," Dr. Saurabh Mehandru of Icahn School of Medicine at Mount Sinai, in New York City, told Reuters Health by email. SARS-CoV-2 initiates infection by attaching the receptor-binding domain of the viral spike (S) protein to epithelial angiotensin-converting enzyme-2 (ACE2), which is expressed by intestinal epithelial cells as well as lung epithelial cells. Cleavage of the S protein by transmembrane serine protease 2 (TMPRSS2) then facilitates viral entry into the host cell. Dr. Mehandru and colleagues examined potenti...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 2 October, 202021 October, 2020